To view this notification widget you need to have JavaScript enabled. This notification widget was easily created with NotifySnack.
Serracor-NK Science & Research

Serracor-NK Science & Research

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Testimonials are Individual Results. Your results may vary. Copyright © 2004 Biomedic Labs. All rights reserved Terms & Conditions.

Enteric coated Serrapeptase and Nattokinase: Why is it important?
Most nattokinase and serrapeptase brands on the market are not enteric coated, which means they can lose a significant portion of their fibrinolytic activity and effectiveness in the acidic environment of the stomach. The enteric coating of our Serracor-NK SEBkinase blend allows these sensitive enzymes to survive the acidic conditions of the stomach, thus allowing them to pass into the circulatory system maintaining high activity levels.*

The pH resistant enteric coating will disintegrate after it enters the alkaline environment of the intestines. If your enzyme formula is not enteric coated, you may be wasting your money (to learn more about enteric coating used in AST Enzymes products, please click the"Compare" tab).

How do Fibrinolytic Units (FU's) relate to enteric coating?
Enzyme activity measured in fibrinolytic units does not mean anything if the enzymes are destroyed and/or denatured in the high acidic conditions of the stomach. Under these conditions, our laboratory tests have consistently shown that serrapeptase and nattokinase lose significant activity when exposed to low pH (such as those in the stomach). In contrast, our enteric coated nattokinase and serrapeptase (the original SEBkinase formula) perform at greater activity levels in the same low pH conditions.

Enzyme Stabilization with BPPS®
The Bioactive Protein Peptides System (BPPS) is a system of peptides used to stabilize and enhance the activity of enzymes.

The Bioactive Protein Peptides System was developed by Specialty Enzymes and Biotechnologies (SEB) specifically for enzyme stability. Stabilizers have been used since SEB began manufacturing enzymes in 1957. The BPPS system was a significant advancement developed by SEB in the early 1990's.

It is true it was not trademarked until 2008, but it was in use long before. The reality is: a pure enzyme is not stable. It requires the addition of stabilizers in order to provide a reasonable shelf life. Because we are the actual manufacturer of enzymes with more than 50 years of manufacturing experience, our research and development team constantly works to improve stability and tolerance to the environments in which the enzymes interact. Marketing companies, on the other hand, will generally have significantly less understanding of the physio-chemical and kinetic properties of enzymes.

Nattokinase Research: Fibrinoyltic Activity

In vitro and in vivo studies have consistently demonstrated the potent fibrinolytic effect of Nattokinase.1 A review of the research on nattokinase demonstrates it may help avoid or reduce the likelihood of deep vein thrombosis, cardiac infarction, pulmonary emboli and stroke. It appears to accomplish this via its fibrinolytic, anti-inflammatory and modulating effect on blood pressure. Studies on hypertension demonstrate an average drop of 10.9% in systolic blood pressure and a 9.7 percent drop in diastolic blood pressure.2,3,4

A study conducted with natto on 12 healthy adults (6 men and 6 women, between the ages of 21 and 55) sought to demonstrate fibrinolytic activity. The volunteers were given 200 grams of natto (the food) before breakfast, and their fibrinolytic activity was tested over time. The results indicate natto generates an increased ability to dissolve blood clots. As a control, researchers later fed the same amount of boiled soybeans to the same volunteers and tracked their fibrinolytic activity. The tests showed no significant change.5

The accumulation of fibrin in blood vessels significantly increases the likelihood of thrombosis formation resulting in a cardiovascular event. For thrombolytic therapy, microbial fibrinolytic enzymes are now much more accepted. The physiochemical properties of this enzyme is becoming well characterized and its effectiveness in thrombolysis in vivo has been further identified.6,7

Nattokinase Benefits & Blood Clots
Blood clots (thrombi) form when strands of fibrin accumulate in the circulatory system. These clots can cause blockage of blood flow. If blood flow is blocked, the oxygen supply to that tissue is cut off and it eventually dies. In the heart, this can result in myocardial infarction (heart attack). In the brain, it can result in strokes or mini-strokes. Deep vein thrombosis can result in pulmonary emboli. All these events can be life-threatening. An in vitro study not only demonstrated the powerful fibrinolytic activity of nattokinase, but also showed the significant reduction in the aggregation of red blood cells and overall lowered whole blood viscosity. The net results are vascular conditions that are less likely to produce blood clots. The authors suggest that nattokinase possesses very real potential as a therapeutic agent in cardiovascular health.8

The process of forming a clot is complex and involves several enzymes. However, the body mainly produces one central enzyme for dissolving a clot, plasmin. It happens that the properties of nattokinase are very similar to plasmin. Nattokinase is particularly effective because it enhances the body's natural ability to fight blood clots in several different ways. It dissolves fibrin directly and appears to enhance the body's natural production of both plasmin and other clot-dissolving enzymes like urokinase. An in vivo study was undertaken to demonstrate the thrombolytic activity of nattokinase, plasmin and elastase on an induced clot in the common carotid artery of laboratory rats. A review of the results indicates that the thrombolytic activity of nattokinase is stronger than that of plasmin or elastase in vivo in this model.9

A fascinating study was conducted to measure the effect of nattokinase in the prevention of deep vein thrombosis and superficial vein thrombosis on extended flights of 7-8 hours on high-risk individuals. The nattokinase group had no thromboses. The placebo group had 5 deep vein thromboses and 2 superficial vein thromboses or 7.6% of 94 individuals. After the flight, the degree of edema was increased by 12% in the placebo group and decreased by 15% in the nattokinase group. The authors concluded that nattokinase was effective in reducing thrombotic events and in controlling edema in high-risk subjects on long flights.10

Serrapeptase Benefits and Respiratory Health
When it comes to the respiratory system, we are constantly at risk of developing health problems, anywhere from the common cold to severe lung diseases. While the cause of any given condition may differ, often time symptoms can manifest themselves and be addressed in similar ways. Clinical testing of serrapeptase reviews its potential with many aspects of respiratory health.

Serrapeptase is widely used in clinical practice in Japan. One research trial in Japan investigated the effect of serrapeptase on sputum properties and symptoms in patients with chronic airway diseases. After 4 weeks of serrapeptase treatment, sputum output, viscosity and sputum neutrophil count decreased significantly. In addition, the frequency of coughing and of expectoration also decreased. The researchers concluded serrapeptase may exert a beneficial effect on mucus clearance by reducing neutrophil numbers and altering the viscoelasticity of sputum in patients with chronic airway diseases.11

Another clinical study reviwed the effect of serrapeptase on the elasticity and viscosity of the nasal mucus in adult patients with chronic sinusitis. Serrapeptase was administered orally for 4 weeks. The dynamic viscosity of the mucus at week 4 was significantly lower than that at week 0. The authors conclude that serrapeptase may have some application in patients with chronic sinusitis.12

The efficacy of serrapeptase was evaluated in a multicentre, double-blind, placebo-controlled study of 193 subjects suffering from acute or chronic ear, nose or throat disorders. After 3-4 days' treatment, significant symptom regression was observed in serrapeptase treated patients. Statistical comparison confirmed the greater efficacy of serrapeptase against all the symptoms examined. It was concluded that serrapeptase has anti-edemic and fibrinolytic activity and supports the body's healthy response to inflammation.13

Serracor-NK® Ingredients:

Enzymes & Herbs

How it Works.


Derived from natto, a traditional Japanese food made from fermented soybeans. Natto has been known for centuries for its positive medicinal properties, particularly for cardiovascular disorders. To make nattô, soybeans are fermented with the beneficial bacteria Bacillus natto (sometimes listed as Bacillus subtilis natto). During fermentation, the Bacilli produce enzymatic proteases, the most important of which is nattokinase. Like other proteases, nattokinase has potent anti-inflammatory activity, as well as several other beneficial properties, including fibrinolytic activity.* A researcher, Hiroyuki Sumi, identified the active enzyme in natto and demonstrated its ability to dissolve vascular blood clots. He called this enzyme "nattokinase," meaning "enzyme in natto."


Derived from a species of bacteria originally found in the intestine of silkworms; the bacteria, Serratia mercesans, produces the enzyme that enables the silkworm to dissolve its silken cocoon and emerge after metamorphosis. Serratia is now grown in cultures to produce serrapeptase by fermentation. Numerous research and clinical studies demonstrate serrapeptase's formidable anti-inflammatory, proteolytic (protein dissolving), mucolytic (mucus dissolving) and fibrinolytic (fibrin dissolving) properties. They also show that scar tissue is greatly reduced and proteins involved in the inflammatory process are effectively digested. Serrapeptase is a protease that has been used in Japan and Europe for over four decades for its anti-inflammatory activity.*


A collective name for the proteolytic (protein-digesting) enzymes found in the pineapple plant (Ananas comosus); known for its digestive as well its anti-inflammatory properties. A good substitute for animal-derived enzymes pepsin and trypsin for both digestive and systemic support due to its activity across a wide pH range*


Obtained from the latex of the fruit of the Papaya tree (Carica papaya); used for centuries as an effective digestive aid.


Catalyzes the break-down of fats into essential fatty acids that are needed for healthy tissues and cells*


Hydrolyze (break-down) proteins like meat, casein, gelatin, soy, fish and other plant and animal proteins to smaller chains of polypeptides (small proteins) and amino acids for easier uptake throughout the body.


Bioflavonoid; strengthens and tones arteries and veins, and provides antioxidant support against free-radicals and inflammation*


Also known as Indian gooseberry (Emblica officinalis); it is a natural, efficacious antioxidant and is one of the richest sources of absorbable vitamin C.


An essential enzyme and cofactor in metabolism that is naturally made and stored in the liver, kidneys and heart; a vital part of energy production and overall cell health*


An essential mineral used as a co-factor by over 350 enzymes in the body; critical part of cardiovascular and nerve physiology. Magnesium helps relax arteries and assists in proper nerve impulse function*


1. Enhancement of the Fibrinolytic Activity in Plasma by Oral Administration of NattokinasesActa Haematol1990; 84:139-143. Hiroyuki Sumia, Hiroki Hamadab, Koichiro Nakanishic, Hajime HiratanicaDepartment of Physiology, Miyazaki Medical College, Miyazaki, Japan;bDepartment of Biochemistry, Oklahoma State University, Okla., USA;cBiochemistry Research Laboratories, JCR Pharmaceuticals, Kobe, Japan

2. Prevent Heart Attack and Stroke with Potent Enzyme that Dissolves Deadly Blood Clots in Hours.Health Sciences Institute, March 2002.

3. Effect of Natto Diet on Blood Pressure.JTTAS, 1995. Maruyama M, Sumi H..

4. Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. Hypertension Research 31, 1583-1588 (2008) Ji Young Kim 1,2, Si Nae Gum2,3, Jean Kyung Paik2,4,5,

5. Purification and Characterization of a Strong Fibrinolytic Enzyme (Nattokinase) in the Vegetable Cheese Natto, a Popular Soybean Fermented Food in Japan. Biochemical and Biophysical Research Communications, Vol. 197, Issue 3, 30 December 1993, pp. 1340-1347 Fujita M., Nomura K., Hong K., Ito Y., Asada A. and Nishimuro S. Jcr Pharmaceut Co Ltd, Biotechnol Res Labs, 3 2 61 Takatsukadai, Nishi Ku, Kobe 65122, Japan

6. Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo. Applied Microbiology and Biotechnology Vol. 69, No. 2, November, 2005, pp- 126-132

7. Nattokinase for prevention of thrombosis. Am J Health Syst Pharm, 63(12): 1121-3 2006
Tai MW , Sweet BV

8. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc 2006; 35(1-2):139-42. Pais E, Alexy T, Holsworth RE, Meiselman HJ

9. Thrombolytic Effect of Nattokinase on a Chemically Induced Thrombosis Model in Rat. Biological & Pharmaceutical Bulletin Vol.18 , No.10 (1995) pp.1387-1391 Mitsugu Fujita1, Kyongsu Hong1, Yae Ito1, Rie Fujii2, Kimio KARIYA2 and Satoshi NISHIMURO3

10. Prevention of Venous Thrombosis in Long-Haul Flights with Flite Tabs: The LONFLIT-FLITE Randomized, Controlled Trial Angiology, Vol. 54, No. 5, 531-539 (2003) M.R. Cesarone, et al.

11. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Nakamura S, Hashimoto Y, Mikami M, Yamanaka E, Soma T, Hino M, Azuma A, Kudoh S. Respirology. 2003 Sep;8(3):316-20. Department of Respiratory Medicine, Tokyo Metropolitan Hiroo General Hospital, Japan.

12. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988;244(6):355-9. Department of Otorhinolaryngology, Mie University School of Medicine, Japan. Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y.

13. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88. Institute of Clinical Otorhinolaryngology, University of Naples, Italy. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, Guarini E, Vesperini G.